Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical c...
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a...
Novanta is a leading global supplier of core technology solutions that give medica...
Novanta is a leading global supplier of core te...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative biopharmaceutical company ...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an in...
Savara is an orphan lung disease company. Savaraâs pipeline comprises Molgradex,...
Savara is an orphan lung disease company. Savar...
Over a century ago in Melbourne, Australia, we made a promise to save lives and pr...
Over a century ago in Melbourne, Australia, we ...
Autolus is a clinical-stage, biopharmaceutical company, focused on the development...
Autolus is a clinical-stage, biopharmaceutical ...
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and se...
Cancer Genetics, Inc. is an emerging leader in ...
Join the National Investor Network and get the latest information with your interests in mind.